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ABSTRACT 
 
Herein we propose a deep learning-based approach for the 
prediction of lung lesion response based on radiomic features 
extracted from clinical CT scans of patients in non-small cell 
lung cancer trials. The approach starts with the classification 
of lung lesions from the set of primary and metastatic lesions 
at various anatomic locations. Focusing on the lung lesions, 
we perform automatic segmentation to extract their 3D 
volumes. Radiomic features are then extracted from the 
lesion on the pre-treatment scan and the first follow-up scan 
to predict which lesions will shrink at least 30% in diameter 
during treatment (either Pembrolizumab or combinations of 
chemotherapy and Pembrolizumab), which is defined as a 
partial response by the Response Evaluation Criteria In Solid 
Tumors (RECIST) guidelines. A 5-fold cross validation on 
the training set led to an AUC of 0.84 ± 0.03, and the 
prediction on the testing dataset reached AUC of 0.73 ± 0.02 
for the outcome of 30% diameter shrinkage. 
Index Terms— radiomics, convolutional neural 
networks, segmentation, quantitative vessel tortuosity 
 
1. INTRODUCTION 
 
Immunotherapy has demonstrated significant efficacy in the 
treatment of non-small cell lung cancer [1, 2]. However, even 
with the help of the FDA-approved biomarkers, e.g. the 
programmed death-ligand 1 (PD-L1) expression, the 
prediction of treatment outcomes for individual patients 
remains challenging. According to studies [3, 4], only around 
20% of patients displaying high levels of PD-L1 expression 
demonstrate positive response to the therapy, which creates 
the need for investigations into additional biomarkers. In 
recent years, radiomics has demonstrated its effectiveness in 
identifying predictive biomarkers in cancer therapies. Unlike 
biomarkers that depend on invasive tumor biopsies [5], and 
unlike novel molecular imaging methods that may be difficult 
to implement in settings outside of tertiary care facilities, 
radiomics utilizes characteristics of lesions visible on non-
invasive CT or MRI images acquired as part of routine 
clinical practice. Intensity, morphology, and texture features 
extracted from regions of interest (ROIs) within and adjacent 
to lesions, along with genomics data and patient metadata, 
can be used to train advanced machine learning models to 
predict meaningful clinical outcomes. 
Recent breakthroughs in immuno-oncology have led to 
increased investigation into radiomic signatures in a large 
variety of cancer trials. Sun et al. [6] introduced a multicohort 
study where they correlated radiomic signatures extracted 
from CT scans with CD8β gene expression to indicate the 
abundance of tumor-infiltrating cytotoxic T-cells in 135 
patients. Saeed-Vafa et al. [7] investigated texture, intensity, 
and shape features in 51 patients and found that the skewness 
of the intensity histogram in Hounsfield units (HU), the root 
mean square of the HU distribution, and the relative volume 
of air in the segmented tumor were most strongly associated 
with response to treatment. Trebeschi et al. [4] analyzed 1055 
lesions from 203 patients undergoing immunotherapy for 
late-stage melanoma and non-small cell lung cancer 
(NSCLC) and reached an average area under the receiver 
operating characteristic curve (AUC) up to 0.83 when 
predicting response of NSCLC lesions to the treatment.  
Alilou et al. [8] expanded beyond features directly related 
to the NSCLC lesions to assess the associated vasculature in 
the surrounding lung region. They defined 35 quantitative 
vessel tortuosity (QVT) features including measurements on 
the tortuosity, curvature, volume, and overall branching 
number to predict response in 112 patients and achieved an 
average AUC of 0.73. 
Here we introduce a radiomics solution for the prediction 
of lesion-level response in NSCLC trials. Starting with 2D 
manual delineations of lesion boundaries created by expert 
radiologists, we first trained a convolutional neural network 
(CNN) to identify lung lesions automatically from the entire 
set of primary and metastatic lesions. Second, a semi-
supervised algorithm was employed to train a CNN to extend 
the segmentation of lesions from 2D to 3D. In the third step, 
radiomic features, including conventional features extracted 
using a standard tool known as PyRadiomics [9] and 
extended QVT features, were extracted from the 3D lesion 
segmentations of the pre-treatment and first on-treatment 
scans. These features were used to train classifiers to predict 
which lesions would shrink at least 30% in diameter during 
treatment, which aligns with the definition of partial response 
per the Response Evaluation Criteria In Solid Tumors 
(RECIST) guidelines [10] in the last step. 
The proposed solution was trained on a set of 844 lung 
lesions from 574 patients selected from one trial and reached 
an average AUC of 0.84 ± 0.03 in a 5-fold cross validation. 
The testing of the solution on a separate trial with 222 lung 
lesions from 176 patients led to an average AUC of 0.73 ± 
0.02, which demonstrated the effectiveness of the proposed 
approach in predicting lung lesions’ response to the therapy. 
This work includes three major contributions. First, it 
outlines a complete radiomics solution with deep neural 
networks facilitating the automated selection of lesions, the 
automated segmentation of 3D lesion volumes, and the 
prediction of lesion shrinkage. The framework is appropriate 
for handling modern large-scale oncology trials. Second, all 
deep CNN models used in the analysis are validated 
rigorously. Finally, it introduces QVT and fractal dimension 
features to supplement the conventional PyRadiomics 
features to improve prediction accuracy. 
 
2. METHOD AND MATERIALS 
 
2.1. Data description 
 
Clinical CT images are acquired for two trials for NSCLC. 
Trial A consists of 10,076 lesion scans from 1,004 patients in 
stage II or stage III receiving a combination of 
Pembrolizumab [11] and chemotherapy as second line 
immunotherapy. Trial B consists of 3,580 lesion scans from 
273 patients in stage III receiving a combination of 
Pembrolizumab and chemotherapy as first line 
immunotherapy. Most images are acquired with intravenous 
contrast agent unless it is prohibited by the medical 
conditions of patients. For each patient, the baseline scan is 
acquired at the start of the treatment, and the first scan after 
the baseline scan is acquired with a 12-week interval. 
Additional scans are then acquired at 6-week intervals 
afterwards. The imaging protocols are reviewed and 
approved by the Institutional Review Board. Note that each 
CT image may contain multiple lesions and that the same 
lesion could be scanned longitudinally at multiple time 
points, leading to multiple lesion scans. For each lesion scan, 
a 2D manual delineation is provided by expert radiologists 
performing RECIST 1.1 analysis. To ensure consistency in 
feature extraction, CT volumes are resampled to isotropic 
voxel size of 0.75×0.75×0.75 mm3 determined by the median 
of in-plane resolution in all volumes. 
 
2.2. Lesion classification by location 
 
The identification of lung lesions is a critical problem 
because of the various primary and metastatic lesion 
locations, including lung, mediastinum, liver, spine, 
subcutaneous tissue, neck, and abdomen. We solve this 
problem by training a binary classification CNN. 
Specifically, as shown in Figure 1, a ResNet [12] with 25 
convolutional layers is trained on 2D patches of 192×192 
pixels cropped from the RECIST slice, centered on the 2D 
manual lesion delineations. We train the ResNet-25 classifier 
with around 9,000 lesions from 4 previous cancer trials with 
imaging protocols similar to those of Trials A and B. The 
dataset is labeled independently by 3 experts and the 
consensus binary labels (lung cancer or others) are used to 
train the CNN classifier. When applied to 896 randomly 
selected images from this dataset, the classifier reaches an 
overall accuracy of 98.5% with no bias toward either class. 
 
2.3. Semi-supervised 3D lesion segmentation 
 
Lesions are normally segmented manually in 3D prior to the 
extraction of radiomic features. This is infeasible in large 
scale studies such as our own. We adopt the semi-supervised 
approach detailed in [13]. The customized SiBA-Net CNN is 
initially trained using manual delineations on the RECIST 
slices. The trained model is then applied to CT slices adjacent 
to the RECIST slice and the results of the prediction are 
refined and added back to grow the training set. The approach 
iterates until no further improvement can be achieved. Details 
can be found in [13]. 
 
 
Fig. 1. A ResNet-25 CNN classifier (right) to identify lung lesions from candidates (left). An identified lung lesion is outlined in red. 
2.4. Extraction of radiomics features to train classifiers 
 
As shown in Figure 2, the entire lesion segmentation and a 
boundary with a 2 mm margin are extracted as two ROIs. In 
each ROI, a standard PyRadiomics tool with a pre-defined 
template is applied to extract 108 features based on the CT 
image. Since the goal of the study is to predict lesion size 
change, 15 features directly or indirectly related to the 
lesion’s size in 3D are eliminated, leaving 93 features, 
including 3 shape-based features, 16 first-order statistical 
features, and 74 texture features in each ROI. 
 
Fig. 2. Segmentation shown in the CT volume (top left), example 
of the two ROIs (top middle and right), and feature extraction 
based on intensity values, intensity statistics, and ROI shape 
(bottom). 
Following the guidelines from the publication on QVT 
features [14], for each lesion scan, we first train a U-Net CNN 
[15] model to segment the lung from the corresponding CT 
volume. The model is trained with around 100,000 CT slices 
with lung region delineations acquired as part of the Luna16 
challenge [16]. The model reaches DSC=0.98 in the 
validation phase and is considered sufficient for a general 
lung segmentation task. Based on the lung segmentation, as 
shown in Figure 3, blood vessels inside the lung are extracted 
using optimized thresholding. The lesion segmentation mask 
is then placed back into the CT volume, and the vessel trees 
connected to the surface of the lesion are retained for the 
analysis of QVT. Specifically, the skeleton of the vessel tree 
is extracted and broken into branches, where branching points 
are detected by counting the number of neighboring voxels 
on the skeleton. For each skeleton branch, the starting and 
ending voxels are identified, and voxels between the starting 
and ending points are retrieved to form a 3D curve with a 
minimum distance consideration. Tortuosity, defined as the 
ratio between the Euclidean and geodesic distance between 
the starting and ending points of the curve, is extracted, and 
curvature is measured at all points on the curve. As proposed 
in [14], the statistics of the tortuosity and curvature measures, 
the number of branches, as well as the overall vessel tree size 
normalized by its minimum bounding box are collected to 
form a set of 34 features. In addition, we also perform an 
analysis of the fractal dimensions [17] of the vessel tree, 
computed using a box counting method. The fractal 
dimensions at radius 21 to 210 voxels are reported as 10 
additional features.  
 
Fig. 3. Segmentation of vessel tree (left) connected to the tumor and 
the skeleton of the vessel tree (right). 
Based upon the entire set of features extracted, we train a 
random forest classifier, a gradient boosting classifier, and a 
multilayer perceptron (MLP) classifier and compare their 
performances over cross-validations.  
Table 1. Cross validation on Trial A with different combination of features and classifiers (Pyrad = PyRadiomics). Average AUC for 
the ROC curves and the standard deviations are shown. 
 Baseline First follow-up Baseline + First follow-up 
 QVT Pyrad QVT+Pyrad QVT Pyrad QVT+Pyrad QVT Pyrad QVT+Pyrad 
RF 0.60±0.04 0.51±0.05 0.54±0.06 0.62±0.02 0.71±0.05 0.73±0.03 0.65±0.03 0.83±0.03 0.84±0.03 
GB 0.60±0.04 0.51±0.04 0.56±0.05 0.63±0.02 0.70±0.05 0.71±0.04 0.63±0.03 0.82±0.04 0.81±0.05 
MLP 0.60±0.04 0.50±0.04 0.55±0.07 0.64±0.04 0.70±0.04 0.72±0.04 0.63±0.03 0.83±0.04 0.83±0.05 
Table 2. Top-5 features ranked by the random forest classifier and the gradient boosting classifier with the best performance. The 
codes listed are feature acronym, scan time (TP1 for baseline, TP2 for first follow-up), and ROI (L for original lesion segmentation, B 
for lesion boundary). 
Rank Random Forest Feature names Gradient Boosting Feature names 
1 GLSZM_Zone Entropy, TP2, L GLSZM_Zone Entropy, TP2, L 
2 Fractal dimension at r=27, TP2 GLDM Dependence Variance, TP2, B 
3 GLCM Correlation, TP2, L Fractal dimension at r=27, TP2 
4 GLRLM Gray Level Nonuniformity, TP2, L GLRLM Gray Level Nonuniformity, TP2, L 
5 GLRLM Run Length Nonuniformity, TP2, L GLRLM Gray Level Variance, TP2, B 
 
 3. EXPERIMENTS AND RESULTS 
 
Using the trained ResNet-25 classifier, 4,577 lung lesion 
scans from trial A and 1,314 lung lesion scans from trail B 
were identified. Pre-treatment and first follow-up scans were 
then selected from lesions associated with at least 2 
longitudinal scans. Lesions shrinking at least 30% in RECIST 
diameter across the entire study period were labeled “1”; 
others were labeled “0”. Radiomics and QVT features were 
extracted from the lesion and boundary ROIs of both the 
baseline and first follow-up scans. This generated 460 
features from 844 lesions in 574 patients in Trial A and 222 
lesions from 176 patients in Trial B. A random forest 
classifier, a gradient boosting classifier, and a MLP classifier 
were trained with 5-fold cross-validation on the features 
extracted from Trial A and evaluated using AUC as the 
measurement of prediction power. The results in Table 1 
demonstrate that the combination of conventional radiomic 
features extracted using PyRadiomics and QVT features led 
to more accurate predictions. Features extracted from the first 
follow-up scan demonstrated higher prediction power than 
the features extracted from the baseline scan alone. As 
expected, combining all features from both scans led to the 
highest prediction accuracy. The receiver operating 
characteristic (ROC) curves are shown for training and cross-
validation on Trial A and testing on Trial B in Figure 4. 
 
Fig. 4. ROC curves for cross validation on Trial A (top) and testing 
on Trial B (bottom).  
 
Random forest and gradient boosting methods allow us to 
assess the importance of features. The features ranked as the 
top-5 most important are listed in Table 2. Both methods 
ranked texture features describing the heterogeneity of 
lesions as most important.  The Gray Level Size Zone Matrix 
(GLSZM) at the first follow-up scan (p<0.001) was ranked as 
the most important feature by both classifiers. Among the 
QVT features, the fractal dimension at radius of 27 (p<0.001) 
at the first follow-up scan was selected by both classifiers as 
one of the top-5 features. 
 
4. CONCLUSION AND DISCUSSION 
 
A radiomics study was performed on 1,066 lung lesions from 
clinical CT scans of 750 patients in two NSCLC trials. Many 
previously published works were limited to 100-200 patients 
due to their dependence on the availability of manual 3D 
lesion delineations. The scale of our study was made possible 
by the application of deep learning techniques to various 
labor-intensive stages, such as precise identification of lung 
lesions and 3D lesion segmentation. 
Based on segmentation results provided by the deep 
learning models, we defined ROIs and extracted conventional 
radiomics features and novel QVT features from both the 
baseline and first follow-up CT scans. Prediction models 
were trained to predict which lesions would achieve at least 
30% shrinkage during treatment, and the model with the best 
performance was able to reach AUC=0.84 in cross validation 
and AUC=0.73 on a testing dataset. Both random forest and 
gradient boosting classifiers selected multiple texture 
descriptors of the lesions as the features with the highest 
prediction power. GLSZM Zone Entropy of the lesion at the 
first follow-up scan was selected as the top feature, which 
agrees with the findings that lesion heterogeneity properties 
highly correlate with clinical outcomes [18]. The QVT 
features demonstrated less prediction power than the 
conventional radiomics features. However, one of the fractal 
dimension features was ranked in the top-5 by both 
classifiers. Considering the relationship between lung 
vasculature and lesion angiogenesis, more investigations are 
needed to better understand the underlying biological reasons 
for this observation. 
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